InvestorsHub Logo
Followers 11
Posts 690
Boards Moderated 0
Alias Born 11/24/2015

Re: None

Tuesday, 11/24/2015 10:15:40 PM

Tuesday, November 24, 2015 10:15:40 PM

Post# of 108191
FDA approves Lilly Advanced Cancer Drug.

It obviously pays to have pull with the FDA. Lilly drug tested in combo with SOC extended life roughly 2 months with some very big side effect disclaimers. From the NY Times.

The Food and Drug Administration said it had approved Portrazza from Eli Lilly, in combination with two forms of chemotherapy, to treat patients with advanced squamous nonsmall cell lung cancer, the most common type of lung cancer. The treatment will need to carry a “boxed warning” that flags potential fatal risks, including cardiac arrest and sudden death. A 1,093-patient clinical trial showed that patients who received Portrazza, along with the chemotherapy drugs gemcitabine and cisplatin, survived an average of 11.5 months compared with 9.9 months for those who received only chemotherapy treatments.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ADXS News